RT Journal Article
SR Electronic
T1 A Multidisciplinary Treatment Strategy With Conversion Surgery for Hepatocellular Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1761
OP 1766
DO 10.21873/anticanres.16329
VO 43
IS 4
A1 SHIOZAKI, HIRONORI
A1 FURUKAWA, KENEI
A1 HARUKI, KOICHIRO
A1 MATSUMOTO, MICHINORI
A1 UWAGAWA, TADASHI
A1 ONDA, SHINJI
A1 YAMAHATA, YUTO
A1 ISHIZAKI, SHUNTA
A1 ABE, KYOHEI
A1 FUJIOKA, SHUICHI
A1 NAKASEKO, YUICHI
A1 OKAMOTO, TOMOYOSHI
A1 IKEGAMI, TORU
YR 2023
UL http://ar.iiarjournals.org/content/43/4/1761.abstract
AB Background/Aim: Sorafenib was previously the only targeted therapy for hepatocellular carcinoma (HCC). However, pharmaceutical therapy for HCC has undergone remarkable advances in recent years. Herein, we report cases of unresectable advanced HCC responding to pharmaceutical therapy resulting in improved prognosis through surgical intervention. Patients and Methods: Five patients with intermediate and advanced stage HCC treated with lenvatinib followed by hepatectomy between October 2019 and September 2022 were retrospectively reviewed. Patient characteristics, tumor factors, and treatment factors were compared. Results: The median patient age was 66 (60-79) years, and all patients (100%) were male. The median follow-up period was 10.4 months. All five patients received lenvatinib treatment for more than 2 months before surgery. Three patients achieved partial responses and 2 patients had stable disease with modified RESIST in response to lenvatinib. Three patients had a partial pathological response (50% or more tumor necrosis). Four patients underwent R0 resection and 3 cases had no recurrence. Conclusion: Lenvatinib might be useful for intermediate and advanced HCC and long-term survival may be obtained by combining lenvatinib therapy with surgery.